Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States

Autor: Christopher Parker, Fei Fei Liu, Kristen A. Deger, Conrado Franco-Villalobos, Irina Proskorovsky, Scott J. Keating, Sonja Sorensen
Rok vydání: 2023
Předmět:
Zdroj: Advances in Therapy. 40:2355-2374
ISSN: 1865-8652
0741-238X
DOI: 10.1007/s12325-023-02444-x
Databáze: OpenAIRE
Externí odkaz: